Patents by Inventor Randy J. Read
Randy J. Read has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6767545Abstract: A composition and method for treating or preventing infection by Pseudomonas aeruginosa is disclosed. The composition includes a P. aeruginosa pilin peptide modified to prevent oligomerization of the pilin. The method involves administered the composition to a person infected with Pseudomonas are at risk of such infection.Type: GrantFiled: May 24, 2001Date of Patent: July 27, 2004Assignee: Governors of the University of AlbertaInventors: Randall T. Irvin, Randy J. Read, Bart Hazes, Wah Y. Wong, Sastry A. Parimi, Linda M. G. Glasier
-
Publication number: 20020098196Abstract: A composition and method for treating or preventing infection by Pseudomonas aeruginosa is disclosed. The composition includes a P. aeruginosa pilin peptide modified to prevent oligomerization of the pilin. The method involves administered the composition to a person infected with Pseudomonas are at risk of such infection.Type: ApplicationFiled: May 24, 2001Publication date: July 25, 2002Inventors: Randall T. Irvin, Randy J. Read, Bart Hazes, Wah Y. Wong, Sastry A. Parimi, Linda M. G. Glasier
-
Patent number: 6342233Abstract: A composition and method for treating or preventing infection by Pseudomonas aeruginosa is disclosed. The composition includes a P. aeruginosa pilin peptide modified to prevent oligomerization of the pilin. The method involves administered the composition to a person infected with Pseudomonas are at risk of such infection.Type: GrantFiled: June 11, 1999Date of Patent: January 29, 2002Assignee: Governors of the University of AlbertaInventors: Randall T. Irvin, Randy J. Read, Bart Hazes, Wah Y. Wong, Sastry A. Parimi, Linda M. G. Glasier
-
Patent number: 6310043Abstract: Compounds which bind to toxins associated with enteric bacterial infection, compositions including the compounds, methods for the neutralization of toxins in a patient, and methods for the diagnosis of bacterial and viral infections are disclosed. Toxins which can be bound by the compounds include pentameric toxins, for example SLTs, such as those from salmonella, camylobacter and other bacteria, verotoxins from E. coli, cholera toxin, clostridium difficile toxins A and B, bacterial pili from enteropathogenic E. coli (EPEC) and enterotoxigenic E. coli (ETEC) and viral lectins such as viral hemagglutinins. The compounds include a core molecule bound to a plurality of linker arms, which in turn are bound to a plurality of bridging moieties, which in turn are bound to at least one, and preferably, two or more ligands which bind to the toxin. The presence of a plurality of bridged dimers of the ligands is responsible for the increased binding affinity of the compounds relative to the ligands themselves.Type: GrantFiled: May 24, 1999Date of Patent: October 30, 2001Assignee: Governors of the University of AlbertaInventors: David R. Bundle, Pavel Kitov, Randy J. Read, Hong Ling, Glen Armstrong
-
Patent number: 6168928Abstract: The three-dimensional structure of crystalline pertussis holotoxin (PT) has been determined by X-ray crystallography. Crystal structures have also been determined for complexes of pertussis toxin with molecules relevant to the biological activity of PT. These three-dimensional structures were analyzed to identify functional amino acids appropriate for modification to alter the biological properties of PT. Similar procedures may be used to predict amino acids which contribute to the toxicity of the holotoxin, to produce immunoprotective, genetically-detoxified analogs of pertussis toxin.Type: GrantFiled: May 21, 1998Date of Patent: January 2, 2001Assignee: Connaught Laboratories LimitedInventors: Randy J. Read, Penelope E. Stein, Stephen A. Cockle, Raymond P. Oomen, Sheena Loosmore, Michel H. Klein, Glen D. Armstrong, Bart Hazes
-
Patent number: 6018022Abstract: The three-dimensional structure of crystalline pertussis holotoxin (PT) has been determined by X-ray crystallography. Crystal structures have also been determined for complexes of pertussis toxin with molecules relevant to the biological activity of PT. These three-dimensional structures were analyzed to identify functional amino acids appropriate for modification to alter the biological properties of PT. Similar procedures may be used to predict amino acids which contribute to the toxicity of the holotoxin, to produce immunoprotective, genetically-detoxified analogs of pertussis toxin.Type: GrantFiled: June 6, 1995Date of Patent: January 25, 2000Assignees: Connaught Laboratories Limited, University of AlbertaInventors: Randy J. Read, Penelope E. Stein, Stephen A. Cockle, Raymond P. Oomen, Sheena Loosmore, Michel H. Klein, Glen D. Armstrong, Bart Hazes
-
Patent number: 5977304Abstract: The three-dimensional structure of crystalline pertussis holotoxin (PT) has been determined by X-ray crystallography. Crystal structures have also been determined for complexes of pertussis toxin with molecules relevant to the biological activity of PT. These three-dimensional structures were analyzed to identify functional amino acids appropriate for modification to alter the biological properties of PT. Similar procedures may be used to predict amino acids which contribute to the toxicity of the holotoxin, to produce immunoprotective, genetically-detoxified analogs of pertussis toxin.Type: GrantFiled: June 6, 1995Date of Patent: November 2, 1999Assignees: Connaught Laboratories Limited, University of AlbertaInventors: Randy J. Read, Penelope E. Stein, Stephen A. Cockle, Raymond P. Oomen, Sheena Loosmore, Michel H. Klein, Glen D. Armstrong, Bart Hazes
-
Patent number: 5965385Abstract: The three-dimensional structure of crystalline pertussis holotoxin (PT) has been determined by X-ray crystallography. Crystal structures have also been determined for complexes of pertussis toxin with molecules relevant to the biological activity of PT. These three-dimensional structures were analyzed to identify functional amino acids appropriate for modification to alter the biological properties of PT. Similar procedures may be used to predict amino acids which contribute to the toxicity of the holotoxin, to produce immunoprotective, genetically-detoxified analogs of pertussis toxin.Type: GrantFiled: June 6, 1995Date of Patent: October 12, 1999Assignees: Connaught Laboratories Limited, University of AlbertaInventors: Randy J. Read, Penelope E. Stein, Stephen A. Cockle, Raymond P. Oomen, Sheena Loosmore, Michel H. Klein, Glen D. Armstrong, Bart Hazes
-
Patent number: 5962423Abstract: Compounds which bind to shiga-like toxins (SLT) associated with enteric E. coli infection, compositions including the compounds, methods for the neutralization of (SLT) in a patient, and methods for the diagnosis of enteric E. coli infection are disclosed. The compounds include a core molecule bound to a plurality of linker arms, which in turn are bound to a plurality of bridging moieties, which in turn are bound to two or three di- or tri-saccharide moieties. The di- or tri-saccharide moieties themselves are active in binding to the SLTs. The presence of a plurality of bridged dimers of the di- and tri-saccharides is responsible for the increased binding affinity of the compounds relative to the di- and tri-saccharides themselves. The compounds, when administered in a timely fashion to a patient suffering from enteric E. coli infection, inhibit progression of this infection into hemolytic uremic syndrome (HUS).Type: GrantFiled: August 7, 1998Date of Patent: October 5, 1999Assignee: The Governors of the University of AlbertaInventors: David R. Bundle, Pavel Kitov, Randy J. Read, Hong Ling, Glen Armstrong
-
Patent number: 5856122Abstract: The three-dimensional structure of crystalline pertussis holotoxin (PT) has been determined by X-ray crystallography. Crystal structures have also been determined for complexes of pertussis toxin with molecules relevant to the biological activity of PT. These three-dimensional structures were analyzed to identify functional amino acids appropriate for modification to alter the biological properties of PT. Similar procedures may be used to predict amino acids which contribute to the toxicity of the holotoxin, to produce immunoprotective, genetically-detoxified analogs of pertussis toxin.Type: GrantFiled: August 22, 1994Date of Patent: January 5, 1999Assignee: University of AlbertaInventors: Randy J. Read, Penelope E. Stein, Stephen A. Cockle, Raymond P. Oomen, Sheena Loosmore, Michel H. Klein, Glen D. Armstrong, Bart Hazes